JOURNAL HOME CME HOME THIS MONTH PAST ISSUES ETOC COLLECTIONS
AUTHORS REVIEWERS EDITORIAL BOARD FEEDBACK RSS HELP
A&A International Anesthesia Research Society
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a colleague
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via ISI Web of Science (3)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Chabbouh, T.
Right arrow Articles by Ozier, Y.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Chabbouh, T.
Right arrow Articles by Ozier, Y.
Related Collections
Right arrow Anesthetic Techniques
Right arrow Complications
Right arrow Regional Anesthesia

Anesth Analg 2005;101:1847-1848
© 2005 International Anesthesia Research Society
doi: 10.1213/01.ANE.0000184126.57327.C3

REGIONAL ANESTHESIA

Persistent Cauda Equina Syndrome with No Identifiable Facilitating Condition After an Uneventful Single Spinal Administration of 0.5% Hyperbaric Bupivacaine

Thouraya Chabbouh, MD, Claude Lentschener, MD, Mathieu Zuber, MD, Nicole Jude, MD, Bernard Delaitre, MD, and Yves Ozier, MD

Université Paris-Descartes, Faculté de Médecine; Assistance Publique – Hôpitaux de Paris, Hôpital Cochin; Université Paris-Descartes, Faculté de Médecine; Hôpital Sainte Anne, Paris, France

Address correspondence to Claude Lentschener, MD, Department of Anesthesia and Critical Care, Hôpital Cochin, 27 rue du Faubourg Saint Jacques, 75679 Paris Cedex 14, France. Address e-mail to claude.lentschener{at}cch.ap-hop-paris.fr.

We diagnosed cauda equina syndrome 15 h after uneventful single spinal administration of 0.5% hyperbaric bupivacaine 12.5 mg through a 27-gauge pencil-point type needle. No preexisting neurologic disorder was recorded. There was no pain or paresthesia during needle placement or drug injection. The sensory levels were bilateral, symmetric, and caudal to T8. Resolution of most of the symptoms occurred within a few days but some foot drop persisted for 2 yr after the procedure. Bupivacaine neurotoxicity is suggested by the absence of any other identifiable cause for this neurologic deficit.




This article has been cited by other articles:


Home page
 Anesth. Analg.Home page
P. Lirk, I. Haller, H. P. Colvin, L. Lang, B. Tomaselli, L. Klimaschewski, and P. Gerner
In Vitro, Inhibition of Mitogen-Activated Protein Kinase Pathways Protects Against Bupivacaine- and Ropivacaine-Induced Neurotoxicity
Anesth. Analg., May 1, 2008; 106(5): 1456 - 1464.
[Abstract] [Full Text] [PDF]

Home page
 Anesth. Analg.Home page
K. D. Rohm and J. Boldt
Persisting Neurological Symptoms After Uncomplicated Intrathecal Bupivacaine
Anesth. Analg., October 1, 2006; 103(4): 1047 - 1047.
[Full Text] [PDF]

Home page
 Anesth. Analg.Home page
T. Chabbouh and C. Lentschener
Persisting Neurological Symptoms After Uncomplicated Intrathecal Bupivacaine
Anesth. Analg., October 1, 2006; 103(4): 1047 - 1047.
[Full Text] [PDF]


Lippincott, Williams & Wilkins Anesthesia & Analgesia® is published for the International Anesthesia Research Society® by Lippincott Williams & Wilkins with the assistance of Stanford University Libraries' HighWire Press®. Copyright 2006 by the International Anesthesia Research Society. Online ISSN: 1526-7598   Print ISSN: 0003-2999 HighWire Press
Copyright © 2005 by the International Anesthesia Research Society.